Neovacs

company

About

Neovacs, a biotech company, develops several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune and allergic diseases.

  • Paris,Ile-de-France,France
  • 11 - 50

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
€6M
Industries
Biotechnology,Health Care,Medical Device,Therapeutics
Founded date
Jan 1, 1993
Number Of Employee
11 - 50
Operating Status
Active
Stock Symbol
epa:ALNEV

Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). At present, monoclonal antibodies are
widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
8
€36.50M
Neovacs has raised a total of €36.50M in funding over 2 rounds. Their latest funding was raised on Jun 22, 2021 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 22, 2021 Post-IPO Debt €4M Detail
Feb 8, 2021 Post-IPO Debt €1M 1 Detail
Jul 31, 2017 Post-IPO Equity €6M Detail
Jan 6, 2016 Post-IPO Equity €5M 1 Bpifrance Detail
Jun 29, 2015 Post-IPO Equity €7.50M Detail

Investments

Number of Investments
Number of Lead Investments
2
2
Neovacs has made 2 investments. Their most recent investment was on Oct 20, 2021, when Signia Therapeutics raised €1.30M.
Date Company Name
Round Money Raised Industry Lead Investor
Series A €1.30M Medical Yes
Sep 27, 2021 Bio-Detection K9
Series Unknown $5M Biotechnology Yes

Investors

Number of Lead Investors
Number of Investors
3
5
Neovacs is funded by 5 investors. Bpifrance and Novartis Venture Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Bpifrance Yes Post-IPO Equity
Novartis Venture Fund Yes Series Unknown
Debiopharm Innovation Fund Yes Series Unknown
Alpha Blue Ocean Post-IPO Debt
Truffle Capital Series Unknown

Employee Profiles

Number of Employee Profiles
5
Neovacs has 5 current employee profiles, including Board member Jean-Jacques Bertrand
Board member
Executive
Executive
Executive
Employee

Exits

Neovacs has had 1 exits. Neovacs most notable exits include Bio-Detection K9

Date Company Name Exit Type Industry
Sep 30, 2021 Bio-Detection K9 M&A Biotechnology Detail